A Meta-analysis Of Adverse Events In The Treatment Of Hormone-sensitive Prostate Cancer With Luteinizing Hormone Releasing Hormone Drugs Alone And Androgen Deprivation Therapy

ObjectiveProstate cancer is one of the most important tumors in the male urogenital system. Asthe extension of human life, also increased the incidence of prostate cancer.Compare withthe LHRH-a therapy in the adverse reactions, we did the systematic evaluation about theclinical application of MAB therapy for prostate cancer in the world. Methods Wesearched PubMed,Embase,Wanfang Database and CNKI, retrieving randomized controlledtrials (RCTs) of prostate cancer therapy literatures. Based on the literature inclusion andexclusion criteria, we selected the related literatures and evaluated the quality by using theJadad scale.The eligible studies were collected and analyzed using Stata12.1. wecalculated the odds ratio (OR) and its95%confidence intervals (CI), and drew the funelplots for publication bias.Results220clinical research were included with1384patients for study.According to thestandard, involving the comparison of the adverse reactions of monotherapy and MABtherapy in prostate cancer. The results of meta-analysis showed:After monotherapy andMAB therapy, there is no difference in the incidence of “anycomplication”,”transaminases increase”,”gastrointestinal toxicity” and”hot flushes”.Compared with MAB therapy, the incidence of “any serious complication” is lower inmonotherapy (OR:0.23;95%CI:0.09-0.58). ConclusionsThere is no obvious difference in incidence of adverse reactions between these twokinds of therapies, but the MAB reflects better result in the incidence of “any seriouscomplication”.